Skip to main content

Table 2 Summary of demographic and baseline clinical characteristics of the treated MS cohort

From: Circulating EZH2-positive T cells are decreased in multiple sclerosis patients

Characteristics

UNT

IFN

GA

FG

NTZ

N

14

17

15

16

11

Age (years)

28.3 (6.3)

34.8 (7.5)

32.3 (7.9)

30.3 (7.8)

27.7 (14.5)

Female/male (% women)

8/6 (57.2)

9/8 (52.9)

8/7 (53.3)

11/5 (68.7)

7/4 (63.6)

Duration of disease (years)

3.3 (2.7)

5.0 (10.7)

6.7 (5.8)

3.0 (3.8)

6.1 (7.0)

EDSSa

1.8 (1.4–2.5)

1.6 (1.0–2.0)

2.2 (1.5–3.0)

1.6 (1.0–2.0)

2.5 (1.6–3.5)

Numbers of relapsesb

2.0 (0.8)

1.5 (0.8)

2.3 (1.5)

2.2 (0.7)

1.9 (0.6)

  1. Data are expressed as mean (standard deviation) unless otherwise stated
  2. UNT untreated relapsing-remitting MS patients, IFN interferon-beta, GA glatiramer acetate, FG fingolimod, NTZ natalizumab
  3. aData are expressed as mean (interquartile range) and refers to EDSS at the time of treatment onset
  4. bThe number of relapses in the 2 years before treatment onset